X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Abecma (idecabtagene vicleucel) is a CAR T cell therapy that recognizes and binds to BCMA on the surface of multiple myeloma cells. It is approved for the treatment of triple-class exposed relapsed or refractory multiple myeloma.
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
Under the acquisition, Regeneron will have full development and commercialization rights to its pipeline of investigational novel immune cell therapies, including Abecma (idecabtagene vicleucel) along with its discovery and clinical manufacturing capabilities.
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Acquisition January 30, 2024
Details:
Abecma (idecabtagene vicleucel) is a BCMA directed CAR-T cell immunotherapy, for patients with relapsed or refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Abecma (idecabtagene vicleucel) is a CAR T cell therapy that recognizes and binds to BCMA on the surface of multiple myeloma cells, for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM).
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
SC-DARIC33 is a investigational drug-regulated CAR T cell (DARIC) Therapy and T cells activater, which is investigated for the treatment for Acute Myeloid Leukemia.
Lead Product(s): SC-DARIC33
Therapeutic Area: Oncology Product Name: SC-DARIC33
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
The collaboration is focused on an in vivo gene editing treatment for hemophilia A by utilizing 2seventy bio’s megaTAL technology that has the potential to provide a highly specific and efficient way to silence, edit, or insert genetic components.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $40.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration May 01, 2023
Details:
Abecma (idecabtagene vicleucel) is the first-in-class B-cell maturation antigen (BCMA)-directed CAR T cell immunotherapy approved by the FDA for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
The net proceeds will be used for the advancement of the KarMMa trials to support the use of Abecma (idecabtagene vicleucel) in earlier lines of therapy and commercial activities in support of Abecma.
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 28, 2023
Details:
The program is designed for the development of 2seventy bio’s MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene’s proprietary end-to-end technology platform. The program is designed to develop TCR-based therapies.
Lead Product(s): TCR-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Medigene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 18, 2023
Details:
The initial focus of the collaboration is 2seventy bio’s MAGE-A4 TCR program in solid tumors which is being developed as part of a collaboration with Regeneron. MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types.
Lead Product(s): TCR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: JW Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
